EMERALD Trial: An Analysis of Key Biomarkers and Patient Subgroups

Project Oncology®

Host: Jennifer Caudle, DO
Guest: Joyce O'Shaughnessy, MD
The results from the phase III EMERALD trial led to the approval of ORSERDU^® (elacestrant) as the first oral selective estrogen receptor degrader for ER-positive/HER2-negative metastatic breast cancer patients with ESR1 mutations after disease progression following at least one line of endocrine therapy.¹ But given the results from prior analyses, clinicians wanted to better understand the data for elacestrant in subgroups of patients with key clinical or biomarker characteristics, and so a post hoc analysis of elacestrant in these subgroups who typically have a poorer prognosis was conducted. Explore the EMERALD trial and the key outcomes from this subgroup analysis with Dr. Jennifer Caudle and medical oncologist Dr. Joyce O'Shaughnessy.